CDK3 and breast carcinoma: An interesting observation that might merit to be confirmed is the association of CDK3 overexpression due to gene rearrangements with BRCA1 loss of heterozygosity (LOH) in breast cancer, a tumor in which CDK3 activity has been linked to tamoxifen resistance.316